Indeed, in the Effect of Statins on Muscle Function and Performance (STOMP) study, the median onset of statin-associated myalgias—with CPK levels less than 10 times the upper limit of the normal values—was 35 ± 31 days after starting statin therapy, compared to 61 ± 33 days in the placebo group [50]. This evidence concerns the gene PIK3C2A and Myalgia.